-
-
-
-
-
-
-
AbCellera reports positive phase 1 data for menopause drug ABCL635
-
-
-
-
-
-
-
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
-
-
-
-
-
-
-
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
-
-
-
-
-
-
-
AbCellera Reports Full Year 2024 Business Results
-
-
-
-
-
-
-
AbCellera Reports Q2 2024 Business Results
-
-
-
-
-
-
-
AbCellera (ABCL) Misses Q4 EPS by 5c
-
-
-
-
-
-
-
AbCellera Reports Q2 2023 Business Results
-
1,216,595 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

